Please login to the form below

Not currently logged in
Email:
Password:

TiGenix’s Crohn's fistulas treatment wins orphan drug status

FDA designation follows positive trial results

TiGenixBelgian biopharmaceutical group TiGenix is one step closer to getting its first-in-class Crohn’s fistulas disease treatment to the US market following an orphan drug designation from the Food and Drug Administration (FDA).

The drug - currently known as Cx601 - could potentially treat ‘complex’ perianal fistulas in patients with Crohn’s disease who have had an inadequate response to at least one conventional or biologic therapy.

Dr Maria Pascual, vice president regulatory affairs and corporate quality, TiGenix, said: “The granting of orphan drug status by the FDA is a significant step forward in the Cx601 development programme.”

The designation follows results of the phase III ADMIRE-CD II trial, a randomised, double-blind, placebo-controlled study designed to confirm the efficacy and safety of Cx601 - a suspension of allogeneic adipose-derived stem cells.

It was found that a single dose of Cx601 was significantly more likely to heal perianal fistulas in Crohn’s patients and stop them coming back for at least a year compared to placebo.

Pascual added: “The FDA’s recognition of Cx601 as an orphan drug brings a number of potential financial benefits and is aligned with our ongoing work seeking expedited pathways towards product approval in the US.”

The move follows the FDA’s plan to eradicate its orphan designation backlog within 90 days, which was announced by commissioner Scott Gottlieb back in July this year.

Meanwhile, TiGenix and partner Takeda has said it will explore expedited pathways to accelerate the submission and review process for US regulatory approval of Cx601.

Article by
Gemma Jones

24th October 2017

From: Regulatory

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
CSafe Global

CSafe Global is the only global provider of a full line of cold chain solutions and is the world’s largest...

Latest intelligence

How innovating study sites can improve patient recruitment efficiency
There are so many ways that clinical trials have innovated over the last few years. There is now a larger focus on making trials more patient-centric, more virtualised, and more...
PME-MAY21-Cover
Avoiding A Series of Unfortunate Events: launch lessons from lockdown
Chris Ross takes a novel look at launch excellence through the lens of COVID-19 and explores how pharma’s launch leaders are rewriting the story...
6 reasons patients drop out of clinical trials and 6 ways to fix it
If you’ve successfully recruited patients for your clinical trial, but one by one, they begin to drop out, then this information could be for you....